{"schema_version":"secwatch.filing_event.v1","accession":"0001140361-26-036489","form_type":"8-K","ticker":"PDSB","cik":"0001472091","company_name":"PDS Biotechnology Corp","filed_at":"2026-09-14T20:10:46+00:00","discovered_at":"2026-09-14T20:12:00.616058+00:00","generated_at":"2026-09-14T20:12:10.600164+00:00","sec_items":["1.02","5.02","7.01","8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"confidence":"high","headline":"PDS Biotech completes $11.3M PIPE led by Nant; adds Soon-Shiong and Banaag to board","bullets":["Initial closing: issued 16,502,870 shares, 23,498,156 pre-funded warrants, 20,000,514 common warrants; gross $11.3M.","Nant (Soon-Shiong) bought $10M of securities; Milestone Closing obligates Nant ($10M) and AB Group ($1M) to buy more.","Dr. Patrick Soon-Shiong (Class C) and James Banaag (Class A) appointed to board effective Sept 14, 2026.","Redeemed $6M Yorkville promissory note for ~$4.6M in full; no early termination penalties.","Proceeds to repay debt, working capital, and advance PDS0301 into late-stage development."],"urls":{"canonical":"https://secwatch.observer/filing/0001140361-26-036489","json":"https://secwatch.observer/filing/0001140361-26-036489.json","markdown":"https://secwatch.observer/filing/0001140361-26-036489.md","text":"https://secwatch.observer/filing/0001140361-26-036489.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1472091/000114036126036489/0001140361-26-036489-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1472091/000114036126036489/ef20081956_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-09-14T20:12:10.600164+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"8ee771a199","claim":"James Banaag was appointed as Director at PDS Biotechnology Corp.","evidence_excerpt":"the Board of Directors (the “ Board ”) of the Company appointed Dr. Patrick Soon-Shiong and Mr. James Banaag as directors and new members of the Board to fill the vacancies on the Board created from the previously announced increase in the size of the Board from six to eight directors, effective as of the Initial Closing (as defined in the Purchase Agreement), which occurred on September 14, 2026.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1472091/000114036126036489/0001140361-26-036489-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"Director"}],"fact_type":"executive_change"},{"claim_id":"cfe5dabafd","claim":"Patrick Soon-Shiong was appointed as Director at PDS Biotechnology Corp.","evidence_excerpt":"the Board of Directors (the “ Board ”) of the Company appointed Dr. Patrick Soon-Shiong and Mr. James Banaag as directors and new members of the Board to fill the vacancies on the Board created from the previously announced increase in the size of the Board from six to eight directors, effective as of the Initial Closing (as defined in the Purchase Agreement), which occurred on September 14, 2026.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1472091/000114036126036489/0001140361-26-036489-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"Director"}],"fact_type":"executive_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}